Research & Clinical Trials
The Dermatology Clinical Research Unit (DCRU) is dedicated to high quality, innovative and high-impact dermatology research. The Clinical Research team consists of highly qualified, trained and certified research professionals who are committed to assisting in the planning, development, implementation, and regulatory oversight of all phases of clinical trials.
Under the guidance of the Clinical Research Director, Jun Lu, M.D., FAAD, the DCRU conducts clinical research studies on a variety of dermatologic conditions, adhering to a mission of advancing the understanding of skin diseases and discovering novel therapies to benefit dermatology patients.
While conducting many investigator initiated trials, the DCRU also actively partners with various pharmaceutical companies and other academic medical centers to bring revolutionary research studies to UConn Health. The DCRU partners with UConn Health to meet its goals of excellence in patient care, education, and research.
Our Team
Jun Lu, M.D.
Clinical Research Medical Director
Akua Pokuah Sarfo, M.D., PhD
Assistant of Director Dermatology Clinical Research
Ektor Rafti, M.D.
Clinical Trials Research Facilitator
Meg Toro, CCRC
Senior Clinical Research Associate
Sueheidi Santiago, M.D.
Clinical Research Fellow
Seda Gul Sahin
Medical Student
Timothy Klufas
Medical Student
Current Open Studies
Hidradenitis Suppurativa (HS)
- Assessment of Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
- Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Discoid and Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)
Psoriasis
- Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis
- Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis
- Psoriasis (PSO) Registry. A Study of Post Approval Drug Safety and Efficacy
Bullous Pemphigoid
Urticaria
Atopic Dermatitis
- Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis
- Assessment of the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
- Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
- Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab
- Lebrikizumab (LY3650150) to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color
- A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy
- Atopic Dermatitis (AD) Registry. A Study of Post Approval Drug Safety and Efficacy